A lifespan single-cell atlas of the human developing hippocampus benchmarks familial Alzheimer's disease brain organoids.
New disease models, an Amish cohort study and an analysis of repurposing candidates all point at the same target from different directions.
TL;DR
- A bioRxiv preprint presents a lifespan single-cell atlas of the developing human hippocampus as a benchmark for familial Alzheimer's disease brain organoids.
- A second preprint, BRIDGE-AD, reports Alzheimer's disease effectors through interpretable integration of large-scale omics data.
- A medRxiv study examines heritability and rare-variant contributions to Alzheimer disease in the Midwestern Amish, and another analyzes varenicline as a repurposable candidate for ADRD prevention.
A bioRxiv preprint describes a lifespan single-cell atlas of the human developing hippocampus intended to benchmark familial Alzheimer's disease brain organoids. A separate bioRxiv preprint, BRIDGE-AD, says it reveals Alzheimer's disease effectors through interpretable large-scale omics integration. Both are preprints and have not completed peer review. [1] [2]
Population genetics is the second strand. A medRxiv study quantifies heritability and rare-variant contributions to Alzheimer disease in the Midwestern Amish, and a companion medRxiv analysis follows age-related traits and cognitive function in the Collaborative Amish Aging and Memory Project. [3] [5]
Treatment hypotheses appear as computational work rather than trial results. One medRxiv analysis evaluates varenicline as a repurposable drug candidate for ADRD prevention, and a summary in the science-news feed describes research on whether some blood thinners may have an unexpected benefit for Alzheimer's patients. [4] [6]
Why it matters
Alzheimer's drug development has repeatedly failed in late-stage trials, which raises the value of better disease models and of separating genuine causal signals from observational associations. The day's output is model- and cohort-building work that later trials depend on.
Editor's note
All items here are preprints or headline-level summaries without peer review, so confidence is medium and no effect sizes are reported because the collection does not include abstracts.